Release Date: May 06, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

Dynavax Technologies Corp (NASDAQ:DVAX) reported its highest ever first quarter net revenue for HAMB of $65 million, a 36% increase compared to the previous year. The company is on track to achieve the top half of its full-year guidance range for net product sales, projected between $305 to $325 million. Dynavax is advancing its development pipeline with key clinical trial milestones for shingles and plague vaccine programs, and new programs in pandemic influenza and Lyme disease. The company's shingles vaccine program shows promise with comparable immunogenicity and improved tolerability compared to existing market leaders. Dynavax has executed over 85% of its $200 million share repurchase program, demonstrating a disciplined approach to capital allocation and shareholder value.

Negative Points

The company recorded a GAAP net loss of $96 million for the first quarter of 2025, primarily due to the GAAP accounting treatment of debt refinancing. R&D expenses increased to $19 million in the first quarter, up from $14 million the previous year, with expectations for further increases. SG&A expenses rose to $48 million, partly due to incremental proxy-related expenses. An allowance for doubtful accounts of $11 million was recorded due to heightened credit risks from Clover Biopharmaceuticals. The company faces uncertainties in the regulatory environment, particularly with potential changes in FDA requirements for vaccine trials.

Q & A Highlights

Warning! GuruFocus has detected 4 Warning Signs with DVAX.

Q: Why not officially raise the lower end of guidance if there's confidence in hitting the upper half? A: Ryan Spencer, CEO: We are only one quarter through the year, so we think it's prudent to maintain our overall guidance range as our official guidance. We have seen good progress to start the year, which is why we mentioned the upper half of the range.

Q: How do the new pre-clinical programs fit into the longer-term strategy, and does this signal less interest in near-term external business development? A: Ryan Spencer, CEO: We have a balanced strategy focusing on leveraging our core assets and infrastructure. We aim to create value through internal development and corporate development focusing on late-stage commercial assets. We also return capital to shareholders through our share buyback program.

Q: Do you expect the recent quarterly performance to be the new normal, or was there something special about this past winter? A: Don Cassell, Chief Commercial Officer: We saw a fast start in retail with a focus on non-flu vaccines, including hepatitis B, which contributed to the growth. This helped flatten out the seasonality typically seen in past years.

Story Continues

Q: Regarding the upcoming shingles data release, will the Q3 data be sufficient for a go/no-go decision, or is more data needed? A: Ryan Spencer, CEO: The Q3 readout is important for initial decision-making, but more comprehensive data, including long-term durability of the T cell response, will be needed for a final decision to move into a pivotal trial.

Q: How do you view the relevance of your Lyme vaccine program given competitors' progress? A: Ryan Spencer, CEO: We believe our program can establish a leading market share by offering a more approachable regimen. Our adjuvant technology can provide a significant commercial benefit by potentially reducing the number of doses required.

Q: Will the FDA's potential requirement for placebo-controlled trials affect your programs? A: Ryan Spencer, CEO: We don't see it as a major challenge. Our shingles program already received positive feedback for a placebo-controlled study. Future programs might involve both placebo and head-to-head arms to support labeling and competition.

Q: If the shingles readout next quarter doesn't meet the 75% threshold for CD4 T cell levels, will you stop the program? A: Ryan Spencer, CEO: The focus is on the vaccine response rate, including CD4 response rate. The 1-month data is informative, but the 6 and 12-month data will be more critical for decision-making.

Q: Is there an explanation for the potentially slower growth in the hepatitis B market share? A: Don Cassell, Chief Commercial Officer: Year-over-year comparisons are more appropriate due to market seasonality. We expect continued year-over-year growth and are on track with our long-term view of achieving at least 60% market share.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

This article first appeared on GuruFocus.

View Comments